Insulin therapy in type 2 diabetes

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)

Volumn 42, Issue 4, 2002, Pages 602-611

  Campbell, R Keith ^a   White, John R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

AMINO ACID SEQUENCE; GLUCOSE BLOOD LEVEL; HUMAN; MOLECULAR GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW;

AMINO ACID SEQUENCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR SEQUENCE DATA; PATIENT COMPLIANCE;

EID: 0036637419     PISSN: 10865802     EISSN: None     Source Type: Journal    
DOI: 10.1331/108658002763029580     Document Type: Review

References (45)

1. American Diabetes Association Medical Management of Type 2 Diabetes 4th ed Clinical Education Series. 1998 American Diabetes Association Alexandria, Va
2. C.R. Kahn Banting Lecture: Insulin action, diabetogenes, and the cause of type II diabetes Diabetes. 43 1994 1066 1084
3. L. Rosetti A. Giaccari R.A. DeFronzo Glucose toxicity Diabetes Care. 13 1990 610 630
4. J.S. Skyler Insulin therapy in type II diabetes: who needs it, how much of it, and for how long? Postgrad Med. 101 1997 85 96
5. W.T. Garvey J.M. Olefsky J. Griffin The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus Diabetes. 34 1985 222 234
6. M. Harris R.E. Klein T.A. Welborn M.W. Knutman Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis Diabetes Care. 15 1992 815 819
7. R. Klein B.E.K. Klein S.E. Moss Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 102 1984 527 532
8. R.C. Turner C.A. Cull V. Frighi R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012
9. R.K. Campbell J.R. White Overview of medications used to treat type 2 diabetes. In: Medications for the Treatment of Diabetes 2000 American Diabetes Association Alexandria, Va
10. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus N Engl J Med. 329 1993 977 986
11. Y. Ohkubo H. Kishikawa E. Araki Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized, prospective 6-year study Diabetes Res Clin Pract. 28 1995 103 117
12. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33) Lancet. 352 9131 1998 837 853
13. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34) Lancet. 352 9131 1998 854 865
14. K. Malmberg DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus BMJ. 314 7093 1997 1512 1515
15. E.J. Bastyr III C.A. Stuart R.G. Brodows Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAlc Diabetes Care. 23 2000 1236 1241
16. M. Hanefeld S. Fischer U. Julius Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-yearfollow-up Diabetologia. 39 1996 1577 1583
17. A.M. Fontbomme E.M. Eschwege Insulin and cardiovascular disease: Paris Prospective Study Diabetes Care. 14 1991 461 469
18. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe Lancet 354 9179 1999 617 621
19. M. Tominaga H. Eguchi H. Manaka Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose The Funagata Diabetes Study. Diabetes Care. 22 1999 920 924
20. B. Glaser E. Cerasi Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes Diabetes Obes Metab. 1 1999 67 74
21. L. Delia Casa G. del Rio B. Glaser E. Cerasi Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia Am J Med. 90 1991 37S 45S
22. D.Y. Donath D.J. Gross E. Cerasi N. Kaiser Hyperglycemia-induced beta cell apoptosis in pancreatic islets in Psammomys obesus during development of diabetes Diabetes. 48 1999 738 744
23. D.L. Eizirik O.S. Korbutt C. Hellerstrom Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta cell function J Clin Invest. 90 1992 1263 1268
24. Z. Ling D.G. Pipeleers Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation J Clin Invest. 98 1996 2805 2812
25. K. Kosaka T. Kuzuya Y. Akanuma Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment Diabetologia. 18 1980 23 28
26. H. Yki-Jarvinen E. Helve V.A. Koivisto Hyperglycemia decreases glucose uptake in type 1 diabetes Diabetes. 36 1987 892 896
27. H. Ilkova B. Glaser A. Tunckale Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment Diabetes Care. 20 1997 1353 1356
28. L. Groop E. Widen A. Franssila-Kallunki Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus Diabetologia. 32 1989 599 605
29. H. Yki-Jarvinen J. Lindstrom L. Koranyi Pretranslational alterations in GLUT-4 gene expression in type 2 diabetes irrespective of control Diabetologia. 34 suppl 2 1991 A3
30. J.E. Foley A. Kashiwagi M.A. Verso Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-depen-dent diabetics. Measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes J Clin Invest 72 1983 1901 1909
31. M.R. Burge D.S. Schade Current therapies for diabetes: insulins Endocrinol Metab Clin North Am. 26 1997 575 598
32. M.N. Feinglos C.H. Thacker J. English Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes Diabetes Care. 20 1997 1539 1542
33. J.H.J. Anderson R.L. Brunelle P. Keohane Mealtimetreatmentwith insulin analogue improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus Arch Intern Med. 157 1997 1249 1255
34. S.M. Setter C.F. Corbett R.K. Campbell J.R. White Insulin aspart: a new rapid-acting insulin analogue Ann Pharmacother. 34 2000 1423 1431
35. A. Lindholm J. McEwen A.P. Riis Improved postprandial glycaemic control with insulin aspart—a randomized, double-blind cross-over trial in type 1 diabetes mellitus Diabetes Care. 22 1999 801 805
36. P.D. Home A. Lindholm B. Hylleberg P. Round Improved glycemic control with insulin aspart—a multicenter randomized double-blind cross-overtrial in type 1 diabetes patients Diabetes Care. 21 1998 1904 1909
37. P.D. Home A. Lindholm A.P. Riis Improved long-term blood glucose control with insulin aspart versus human insulin in people with type 1 diabetes European Insulin Aspart Study Group. Diabetes. 48 1999 DA358
38. R.E. Ratner I.B. Hirsch J.L. Neifing Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes Diabetes Care 23 2000 639 643
39. J. Rosenstock S.L. Schwartz C.M. Clark Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care. 24 2001 631 636
40. P. Raskin L. Klaff R. Bergenstal A 16-week comparison of the novel insulin analogue insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes Diabetes Care. 23 2000 1666 1671
41. P. Roach L. Yue V. Arora Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group Diabetes Care 22 1999 1258 1261
42. B. Zinman H. Tildesley J.-L. Chiasson Insulin lispro in CSII: results of a double-blind crossover study Diabetes. 46 1997 440 443
43. J.B. Buse The use of insulin alone and in combination with oral agents in type 2 diabetes Primary Care. 26 1999 931 950
44. J.R. White The pharmacologic reduction of blood glucose in patients with type 2 diabetes mellitus Clin Diabetes. 16 1998 58 67
45. Lantus [package insert]. Kansas City, Mo: Aventis Pharmaceuticals Inc; 2001. Available at: www.lanutus.com/professional/home.html . Accessed June 4, 2002.